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Immunotherapy targeting ganglioside antigens is a powerful tool for the treatment of high
risk neuroblastoma. However, only treatment with anti-GD2 antibodies has been used in
clinical practice and other options may be pursued. We report the use of racotumomab, an
anti-idiotype vaccine against N-glycolyl neuraminic acid (NeuGc)- containing gangliosides,
eliciting an immune response in a child with relapsed neuroblastoma expressing the
NeuGcGM3 ganglioside.
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INTRODUCTION
This is a 4-year-old female patient who presented with diffuse
pain in lower limbs leading to walking problems and a 1-month
history of intermittent fever and generalized pallor. Physical
examination showed right eye proptosis and an abdominal mass.
Laboratory tests showed anemia (hemoglobin 7.5 g %) and ele-
vated LDH. The child was hospitalized at another center for
evaluation. A CT scan of the abdomen revealed a large calci-
fied abdominal mass originating from left adrenal gland. She was
referred to our Hospital for further treatment. At our hospital,
neuroblastoma cells were evident at a bone marrow examina-
tion. Malignant cells were positive for 1p deletion and showed
MYCN amplification. Metaiodobenzylguanidine (MIBG) scintig-
raphy revealedmultiple tumoral foci in skull, spine, and left upper
quadrant of the abdominal mass. Urinary catecholamines deter-
mination revealed elevated norepinephrine levels and vanillyl
mandelic acid (VMA).
Therefore, with a diagnosis of Stage 4 neuroblastoma belong-
ing to the high risk group, chemotherapy was prescribed,
including 5 cycles of a standard induction regimen (Matthay,
1999). Evaluation after induction chemotherapy showed pro-
gressive disease in the abdominal tumor and in the bone
marrow.
A second line regimen including 3 cycles of topotecan and
carboplatin was given. A repeated response evaluation revealed
persistent bone marrow infiltration, progressive disease in the
orbit with intracranial extension, thoracic and lumbar vertebrae
as well as a persistent left heterogeneous retroperitoneal mass
10× 8× 8 cm and high catecholamine levels. The patient had
significant malaise and widespread pain. The disease was deemed
refractory to conventional therapy and she was considered for
experimental treatment.
BACKGROUND
Despite advances in the treatment of pediatric malignancies, can-
cer is the second most common cause of death in children over
1-year-old in developed countries. In Argentina, it accounts for
the third leading cause of death in children preceded by accidents
and congenital malformations (Scursoni et al., 2011). Children
with primary multifocal, refractory or relapsed malignant solid
tumors still have a very poor prognosis. On the other hand,
most therapies are associated with significant toxicity, causing
long-term morbidity.
Neuroblastoma is a cancer of the sympathetic nervous sys-
tem accounting for about 12% of cancer-related deaths in
children under 15-years old. It is a heterogeneous disease in
which up to 50% of patients have a high-risk behavior char-
acterized by widespread dissemination and poor long-term
survival, even when using intensive multimodal treatments.
Significant improved outcomes were published nearly a decade
ago with the use of myeloablative therapy with stem-cell
rescue, followed by differentiation treatment with isotretinoin
(Matthay, 1999).
However, over 50% of patients receiving standard therapy
relapse and ultimately die from the tumor. Consequently, the
major obstacle to cure, once remission is achieved, is the
chemotherapy-refractory disease that eludes the current methods
for its detection. This failure has led to a resurgence of inter-
est in alternative methods of disease eradication. Immunotherapy
became a particular and hopeful option.
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DISCUSSION
EXPERIMENTAL TREATMENT: IMMUNOTHERAPY
Our patient was eligible for our phase I study of the mon-
oclonal anti-idiotype antibody racotumomab (formerly called
1E10), that targets NeuGc-containing gangliosides. In this case,
biopsy specimens from the bone marrow showed marked posi-
tivity to the ganglioside antigen NeuGcGM3 (Figure 1) (Scursoni
et al., 2011). As scheduled by the protocol, she received 3 intra-
dermal applications of alum-adsorbed racotumomab at a dose of
0.15mg each in the anterior left forearm. The drug was admin-
istered on an ambulatory basis every 14 days and the child
presented only mild side effects such as localized painless ery-
thema 3 cm in diameter at the injection site that appeared 8 h
after application and disappeared within 24 h, without any treat-
ment. No laboratory alterations or other evidence of toxicity was
observed.
One month after the last monoclonal antibody dose, she had
progressive disease in the orbital metastasis and complained of
generalized bone pain and lower limb paresis. A nuclear magnetic
resonance imaging (MRI) was performed revealing spinal cord
compression. Because of that, local orbital and spinal radiother-
apy was carried out for palliation. The patient died one month
after this episode due to disease progression.
Along with follow-up laboratory results, serum samples were
drawn to assess the induction of antigen-specific antibodies. The
patient developed a positive anti-racotumomab IgG response
(Figure 2A). The reactivity against iorC5, an isotype-matched
murine monoclonal antibody was significantly lower than that to
racotumomab, underscoring the immunodominance of racotu-
momab idiotype. Most interestingly, anti-NeuGcGM3 IgM anti-
bodies were also induced. The anti-ganglioside response was
observed two weeks after the second racotumomab immuniza-
tion (Figure 2B), but faded away later and was not detectable
one month after the third immunization. The anti-ganglioside
response was NeuGcGM3 specific, as no significant reactivity was
observed against N-acetyl (NeuAc) GM3 (Figure 2B).
FIGURE 1 | Nests of maturing ganglion cells. Inset: positivity of these
cells for 14F7 ganglioside.
IMMUNOTHERAPY IN NEUROBLASTOMA
Current conventional therapies against neuroblastoma have
proven inadequate to treat advanced and refractory disease. The
future success of immunotherapy against neuroblastoma should
include the combination of treatment modalities for target-
ing minimal residual disease. Neuroblastoma is the archetypical
pediatric tumor for the use of immunotherapy (Modak and
Cheung, 2007). The most widely used immunotherapy for neu-
roblastoma consists of murine or humanized-murine chimeric
monoclonal antibodies directed against GD2, a disialoganglio-
side expressed in tumors of neuroectodermal origin. However,
GD2 is poorly immunogenic, so this antibody had to be com-
bined with immunomodulators to elicit a significant response,
which was also associated to severe toxicity (Gray and Kohler,
2009). This treatment is not available outside clinical trials, so
it is not an option for patients with neuroblastoma in develop-
ing countries. There is good evidence that many children with
neuroblastoma elicit an immune response against their tumor.
Although these spontaneous immune responses are generally
weak and fail to control tumor growth, they have the potential to
FIGURE 2 | Antibody response elicited by racotumomab immunization.
Serum samples obtained two weeks after the second immunization were
assessed for anti-mouse (A) and anti-ganglioside (B) antibodies. (A) Plates
were coated with either racotumomab or an isotype-matched monoclonal
antibody (iorC5). Overlaid titration curves show a significantly stronger
reactivity toward racotumomab. (B) Plates were coated with N-glycolyl
GM3 or N-acetyl GM3. No significant binding to N-acetyl GM3 was
observed.
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be manipulated to provide a highly specific therapy for minimally
disseminated neuroblastoma. Many different immunotherapy
approaches have emerged over the last decades, but only a small
number of these have achieved the level of clinical studies with
relevant but arbitrary clinical responses, providing evidence that
the immune system is capable, under certain conditions, of con-
trolling and eradicating the tumor (Gray and Kohler, 2009).
GD2 is uniformly expressed in neuroblastomas (Wayne et al.,
2010). Its function is not fully established but is thought to
play a major role in tumor cell attachment to extracellular
matrix proteins. GD2 expression in normal tissues of adults
and children is restricted to the central nervous system, periph-
eral nerves, and skin melanocytes (Modak and Cheung, 2007).
Due to the relatively tumor-selective expression combined with
its presence on the cell surface, GD2 is an attractive target for
this kind of therapy and immunotherapy with the humanized
monoclonal antibody 14.18 showed improved results combined
with high dose therapy, autologous stem cell rescue, and differ-
entiation therapy in a randomized trial (Modak and Cheung,
2007).
Active specific immunotherapy is a promising field in can-
cer research. NeuGc gangliosides, particularly the NeuGcGM3
ganglioside, have received considerable attention as a privileged
target for cancer therapy (Fernandez et al., 2010). They are usu-
ally undetectable in healthy human tissues and fluids, but widely
expressed in tumor tissues, including neuroblastoma and other
pediatric solid tumors (Fernandez et al., 2010). Glycosidic chains
of gangliosides contain at least one sialic acid residue. Sialic acid
may have some variations, with the most common versions in
mammals: Neu-Ac and Neu-Gc. Many of these glycolipid com-
pounds are abundantly expressed in tumor cells, being regarded
as promising targets for immunotherapy, as is the case of the
NeuGcGM3 monosialoganglioside.
Clinical trials have been carried out with murine mono-
clonal anti-idiotype racotumomab to treat adult tumors such
as melanoma, breast, and lung cancer, which express surface
NeuGc gangliosides. These studies showed a correlation between
development of antibodies against NeuGcGM3 and increased sur-
vival time (Guthmann et al., 2006; Oliva et al., 2006; Hernandez
et al., 2008; Fernandez et al., 2010). Our group reported the
expression of these gangliosides in 85% of the cases of neurob-
lastoma studied (Scursoni et al., 2011). Thus, a Phase I clinical
trial is currently underway at our hospital in pediatric patients
with refractory or resistant neuroblastoma and other neuroecto-
dermic tumors using racotumomab. This vaccine has not been
previously used in children, so we hereby present a case report
of the first patient recruited in the study who received this
vaccine.
This Phase I clinical trial is being carried out in Garrahan
Hospital in pediatric patients diagnosed with cancer express-
ing NeuGc gangliosides and who have been previously refrac-
tory or resistant to conventional cancer treatments. The main
objective is to evaluate the acute toxicity and maximal toler-
ated dose and, secondly, immunological and clinical response to
treatment with racotumomab. This is the first time that this mon-
oclonal antibody is used in children. Since this is a treatment
directed to minimally disseminated disease, it is probable that
very few patients with refractory disease would present a clinical
response. Racotumomab was immunogenic and induced a strong
anti-mouse IgG response with marked specificity to racotu-
momab idiotype. Furthermore, a transient IgM response specific
for NeuGcGM3 was also observed after the second adminis-
tration of racotumomab. No anti-ganglioside IgG response was
detected, which is in line with the need for an extended booster
regimen to elicit the antibody class switch (Guthmann et al.,
2006). The immunodominance of racotumomab idiotype and
the NeuGcGM3 specificity of the anti-ganglioside response have
been described earlier for adult patients under a 1mg racotu-
momab immunotherapy regimen (Guthmann et al., 2006). The
present results, obtained from a 4-year-old infant receiving a
0.15mg dose-level, suggest that a similar immunogenicity might
be elicited in infants, thereby warranting further investigation of
racotumomab in pediatric cancer immunotherapy.
CONCLUDING REMARKS
Interest in immunotherapy for pediatric cancer is increasing.
However, most therapies are still experimental. The challenges
for the next decade involve translating pre-clinical treatment out-
comes into effective treatments for patients and making these
treatments available in developing countries where toxicity is a
severe problem.
Racotumomab vaccination proved to elicit an immune
response with a favorable toxicity profile. A Phase I trial is accru-
ing patients to fully characterize its toxicity profile and it may
become an innovative alternative for treatment of neuroblastoma
and other embryonal pediatric malignancies.
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